Company Information

CAPLIN POINT LABORATORIES LTD.

NSE : CAPLIPOINTBSE : 524742ISIN CODE : INE475E01026Industry : Pharmaceuticals & DrugsHouse : Private
BSE2366.9516.8 (+0.71 %)
PREV CLOSE ( ) 2350.15
OPEN PRICE ( ) 2373.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 20822
TODAY'S LOW / HIGH ( )2303.00 2486.65
52 WK LOW / HIGH ( )1179.95 2397.95
NSE2380.5018 (+0.76 %)
PREV CLOSE( ) 2362.50
OPEN PRICE ( ) 2364.15
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 547998
TODAY'S LOW / HIGH( ) 2300.40 2490.00
52 WK LOW / HIGH ( )1178 2398
ChairmanC C Paarthipan
Managing DirectorSridhar Ganesan
Company SecretaryG Venkatram
Independent DirectorR Vijayaraghavan
Non Executive Independent DirectorCK Gariyali
R Nagendran
S Deenadhayalan
Incorporation Year : 1990

Registered Office :

Address : 3rd Floor, “ Ashvich Towers”,No.3, Developed Plots Industrial Estate,Perungudi Chennai,
Tamil Nadu-600096 .

Phone : 044-24968000 / 8012772888 / 71148000

Email :  info@caplinpoint.net  

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.